Liver Transplant Failure and Rejection

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Liver Transplant Failure and Rejection trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 1/2

NCT07053488

CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection

This early-phase clinical trial will assess the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to reduce immunogenicity before transplantation.…

China90 participantsStarted 2025-06-01

Treatment: Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver

RecruitingNot Applicable

NCT01757730

Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues

Magnetic resonance elastography is a novel non-invasive MRI technique to obtain stiffness of soft tissues such as liver, heart, kidneys, etc. In this imaging te…

United States1,000 participantsStarted 2012-03

All recent trials (18 shown)

SuspendedPhase 4

NCT04756063

Parenteral Ascorbic Acid Repletion in TransplantatIon

A single-center, randomized, double-blinded placebo-controlled trial is proposed to investigate administration of supraphysiologic doses of ascorbic acid (vitam…

United States90 participantsStarted 2026-05

Treatment: Ascorbic acid, Placebo

Active — Not RecruitingPhase 1/2

NCT05234190

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression with…

Belgium, Spain33 participantsStarted 2022-01-21

Treatment: QEL-001

Liver Transplant Failure and Rejection

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection

Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues

All recent trials (18 shown)

Parenteral Ascorbic Acid Repletion in TransplantatIon

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection

Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues

All recent trials (18 shown)

Parenteral Ascorbic Acid Repletion in TransplantatIon

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients

Histologic Evolution of Patients With Liver Transplantation

Mortality, Morbidity and Risk Factors of Liver Retransplantation

Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in F…

Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients

Dual Hypothermic Oxygenated Machine Perfusion in Liver Transplantation Using Allografts From Donors After Brain Death

Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum Studies

Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

Antibodies and Liver Retransplantation

Donor Simvastatin Treatment in Organ Transplantation

Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival

Use of N-Acetylcysteine During Liver Procurement

Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study